Daniel Sieberg, science and technology correspondent for CBS News and blogger for Tech Talk recently went searching for online sites offering help and hope for those seeking insight into the world of cancer.

Sieberg went about his search by typing into Google the word cancer. Thrown back at him were more than 250 million results. Overwhelmed by the sheer volume of information and misinformation, Sieberg sifted and sorted through everything that faced him -- and he narrowed down the results to his favorite five.

Sieberg is right on with his picks, and while I personally would have included The Cancer Blog as a source loaded with accurate, reliable, and inspiring information, I still commend Sieberg for so effectively hunting down some very good cancer resources. For what it's worth, I happen to highly recommend them myself.

American Cancer Society
National Cancer Institute
WebMD
M.D. Anderson Cancer Center
Leroy Sievers Blog

Metastatic colorectal cancer is commonly treated with a regime called FOLFIRI, consisting of 5-fluorouracil, Camptosar (irinotecan), and leucovorin. Long term survival with this treatment has shown to have mediocre results.

Erbitux (cetuximab) is a type of targeted therapy called a monoclonal antibody. Erbitux targets EGFR, the epidermal growth factor receptor, and can reduce the spread of cancer.

The addition of Erbitux to the chemotherapy regime FOLFIRI can improve progression free survival compared to just receiving FOLFIRI alone. The CRYSTAL study compared Erbitux/FOLFIRI to FOLFIRI alone for treatment of metastatic colorectal cancer. One thousand patients who had not received any prior therapy after learning of the spread of the disease were enrolled in the Phase III clinical trial.

The study concluded that it was indeed a good idea to include Erbitux with the FOLFIRI in first line treatment for metastatic colorectal cancer. Progression free survival was significantly improved.

More and more we are hearing about monoclonal antibody's like Erbitux. Here is some other information posted on The Cancer Blog about Erbitux:

200 companies, 340 immunotherapy drugs, 600 clinical trials

Terminal cancer patients question worth of remaining life

UK patients angry as new bowel cancer drugs are rejected

First time in 45 years new drug for head and neck cancers

Cancer Drug May Prolong Survival

In 2006, 174,470 people will be diagnosed with lung cancer in the United States. About 92,700 men and 81,770 women will develop the disease -- the leading cause of cancer death among both men and women.

An estimated 162,460 men and women will die of lung cancer this year, accounting for 28 percent of all cancer deaths and taking more lives than colon, breast, and prostate cancers combined. While most people diagnosed with lung cancer will die within the first two years of diagnosis -- this has not changed in 10 years -- some people are cured. There are currently about 333,000 long-term survivors.

Janice R. England has been investigating dumpsites and landfills and cancer clusters for over twenty years. In 1984, she founded People Investigating Toxic Sites, P.I.T.S., to provide information on locations of open and closed dumpsites and landfills, contaminated groundwater, and to investigate illnesses related to contamination of the environment.

P.I.T.S. features an online resource of a state by state list of toxic waste, military ordinance and chemical warfare dumps. According to England, many of these sites are linked to contaminated groundwater, cancer clusters, birth defects and various health problems. She has provided a way for you to find out if you live, work, play or send your children to schools that are on or adjacent to these toxic sites. Visit P.I.T.S. to learn more.